Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM

摘要

AbstractLike other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. We discuss reasons and implications of these negative results and the implications for clinical practice and future research.